Table 2.
The p53 and Ki67 immunoreactivity scorings in percentages of all patients divided in five different treatment groups
| Groups | Material | Inflammation | Proliferation (%) | P53 (%) | Haemorrhage |
|---|---|---|---|---|---|
| 1 (MMC) | |||||
| a | Biopsy | +++ | 30 | 20 | + |
| Cystectomy | +++ | 75 | 20 | ++ | |
| b | Biopsy | ++ | 20 | 75 | − |
| Cystectomy | +++ | 15 | 75 | + | |
| c | Biopsy | +++ | 40 | 75 | +++ |
| Cystectomy | NA | NA | NA | NA | |
| 2 (HT) | |||||
| a | Biopsy | + | 60 | 80 | − |
| Cystectomy | +++ | 20 | 40 | ++ | |
| b | Biopsy | + | 30 | 90 | − |
| Cystectomy | ++ | 20 | 40 | − | |
| c | Biopsy | + | 10 | - | − |
| Cystectomy | ++ | 10 | - | + | |
| 3 (MMC + HT) | |||||
| a | Biopsy | +++ | 40 | >75 | − |
| Cystectomy | +++ | 25 | 75 | − | |
| b | Biopsy | +++ | >75 | >75 | + |
| Cystectomy | +++ | 60 | 15 | − | |
| c | Biopsy | +++ | 30 | >75 | + |
| Cystectomy | +++ | 15 | 75 | ++ | |
| 4 (History of MMC + HT) | |||||
| a | Biopsy | + | 10 | 75 | − |
| Cystectomy | + | 20 | − | − | |
| b | Biopsy | +++ | 30 | 25 | − |
| Cystectomy | +++ | 30 | 25 | − | |
| c | Biopsy | ++ | 50 | 20 | − |
| Cystectomy | ++ | 20 | 10 | + | |
| 5 (Control) | |||||
| a | Biopsy | + | 15 | >75 | − |
| Cystectomy | +++ | 40 | >75 | − | |
| b | Biopsy | ++ | 40 | 20 | − |
| Cystectomy | ++ | 40 | 20 | − | |
| c | Biopsy | ++ | 35 | 75 | + |
| Cystectomy | +++ | 35 | 75 | − | |
The extend of inflammation and haemorrhage is semi quantitatively scored (1+ to 3+)
NA not applicable due to absence of residual tumour